ArticleFrontiers in public health2025
Healthcare costs of cutaneous melanoma according to comorbidity patterns: a population-based study from the Regional Cancer Registry of the Veneto Region.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous malignant melanoma represents a notable public health issue, characterized by a rapidly increasing incidence, particularly among younger populations. Despite progress in early detection and treatment modalities, this rising trend exacerbates the healthcare system's burden. Limited research has been conducted on the impact of comorbidities on overall and melanoma-specific healthcare costs incurred by patients with melanoma. The objective of this study is to assess how various comorbidity patterns influence healthcare costs in this patient population. Methods: This retrospective cohort study reviewed data from the Regional Cancer Registry of the Veneto Region (RTV) for melanoma diagnoses in 2019 and 2021. Patients were grouped into specific comorbidity clusters using latent class analysis, and the effect of these patterns on melanoma healthcare costs was evaluated from a health system perspective, considering only the direct costs incurred by the regional health care service. Results: The study included 2,978 cases of incident melanoma. The 2,114 patients with comorbidity data available were categorized into three comorbidity clusters: Circulatory-Metabolic-Respiratory, Psychosocial-Pregnancy related, and Multiorgan-Trauma. The mean unadjusted overall and melanoma-specific cumulative expenditure per patient increased with the number of comorbidities: melanoma-specific healthcare resources were € 13,537 (no comorbidity), € 16,828 (one comorbidity), € 20,396 (Multiorgan-Trauma cluster). Hospitalizations were the primary driver of cost escalation, particularly for patients with Multiorgan-Trauma comorbidities. Conclusion: Comorbidity patterns significantly impact melanoma management and related healthcare costs. Understanding these patterns can help optimize resource allocation and improve patient management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.